Browsing by Author "Agrawal, Bimal K."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Cross-immunity and trained immunity in explaining variable COVID-19 mortality�Guidance for future pandemics
    (John Wiley and Sons Inc, 2021) Chakrabarti, Sasanka; Chakrabarti, Sankha S.; Kaur, Upinder; Agrawal, Bimal K.; Ganguly, Upasana; Jin, Kunlin
    [No abstract available]
  • Thumbnail Image
    Publication
    Protective effects of cyclosporine A on neurodegeneration and motor impairment in rotenone-induced experimental models of Parkinson's disease
    (Elsevier B.V., 2022) Singh, Sukhpal; Ganguly, Upasana; Pal, Soumya; Chandan, Gourav; Thakur, Rahul; Saini, Reena V.; Chakrabarti, Sankha Shubhra; Agrawal, Bimal K.; Chakrabarti, Sasanka
    The development of neuroprotective drugs targeting mitochondria could be an important strategy in combating the progressive clinical course of Parkinson's disease. In the current study, we demonstrated that in SH-SY5Y cells (human dopaminergic neuroblastoma cell line), rotenone caused a dose-dependent (0.25�1 ?M) and time-dependent (up to 48 h) loss of cell viability and a loss of cellular ATP content with mitochondrial membrane depolarization and an increased formation of reactive oxygen species; all these processes were markedly prevented by the mitochondrial permeability transition pore blocker cyclosporine A, which did not affect complex I inhibition by rotenone. The nuclear morphology of rotenone-treated cells for 48 h indicated the presence of both necrosis and apoptosis. We then examined the effects of cyclosporine A on the rotenone-induced model of Parkinson's disease in Wistar rats. Cyclosporine A significantly improved the motor deficits and prevented the loss of nigral dopaminergic neurons projecting into the striatum in rotenone-treated rats. Being a marketed immuno-suppressive drug, cyclosporine A should be further evaluated for its putative neuroprotective action in Parkinson's disease. � 2022 Elsevier B.V.